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Assessment of late effects in a cohort of female Hodgkin’s lymphoma patients treated with mantle radiotherapy, identified from the
DoH breast cancer screening recall showed high mortality and frequent undiagnosed abnormalities in tissues affected by
radiotherapy. With increasing age, this patient group may suffer premature cardiac and respiratory morbidity.
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Prolonged disease-free survival is attainable in up to 90% of
patients presenting with early-stage Hodgkin’s lymphoma (HL)
(Henry-Amar and Joly, 1996). Current treatment usually involves
multiagent chemotherapy combined with limited field radio-
therapy in selected patients. However, until recently, the standard
radiotherapy regimen for supradiaphragmatic HL was the mantle
field (Deniz et al, 2003; Horwich and Swerdlow, 2004).
Young women who received mantle radiotherapy are at
increased risk of breast cancer (Swerdlow et al, 2000; Deniz
et al, 2003; Travis et al, 2003; Horwich and Swerdlow, 2004; Kenney
et al, 2004). The risk is proportional to radiation dose, and time
from treatment (Hancock et al, 1993a; Wolden et al, 1998).
Younger age at the time of treatment gives the greatest risk
(Hancock et al, 1993a; Bhatia et al, 1996). At 25 years of follow-up,
the cumulative risk of breast cancer for women treated between 10
and 19 years of age is reported as 15–33%, and for those treated
between the ages 20 and 29 years, 15–25% (Horwich and
Swerdlow, 2004). In 2003, the UK Department of Health launched
a ‘Patient Notification Exercise’ to inform patients of the increased
breast cancer risk. The exercise mandated recall of all women with
HL, who were diagnosed at or below the age of 35 from 1962
onwards. Mantle radiotherapy is associated with other long-term
complications including second malignancies, and disorders of the
thyroid, heart and lung (Morgan et al, 1985; Gustavsson et al, 1990;
Allavena et al, 1992; Gustavsson et al, 1992; Henry-Amar and Joly,
1996). The aim of our study was to investigate the incidence of late
effects in women recalled in the UK ‘Patient Notification Exercise’.
MATERIALS AND METHODS
Patients were identified from a network database, according to the
following criteria: diagnosis of HL after 1962 and before the age of
35 years, and mantle radiotherapy. Women with a known history
of breast cancer were excluded. Patients were offered a clinic
appointment for counselling regarding breast cancer risk. Patients
who accepted were asked if they were willing to participate in a
study of late effects. The study was approved by the South Sheffield
Research Ethics Committee and all patients gave written informed
consent.
Late effects study protocol
Patients underwent a clinical evaluation including examination of
the skin and thyroid. In addition, the following investigations were
performed:
Blood: Serum thyroid-stimulating hormone (TSH), free T4 (fT4),
parathyroid hormone and corrected calcium.
Cardiac: Echocardiogram and electrocardiogram.
Respiratory: Spirometry and diffusion capacity (TLCO).
Measurement and interpretation of results
Serum measurements were considered against the laboratory
normal range. Spirometry and transfer factors results were
expressed as the percentage of predicted. All cardiology and
respiratory tests were reviewed by a single cardiologist and
respiratory physiologist, respectively. Tests were reviewed without
the knowledge of patients’ characteristics or other study data.
Cardiac and respiratory abnormalities were classified as follows:
Major cardiac abnormality:
  A reduction in ejection fraction to less than 50% (or LV
fractional shortening of less than 28%).
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s  Regurgitant valvular lesion of more than mild severity.
  Valvular stenosis.
  Raised pulmonary artery pressure (440mmHg) or right heart
dilatation.
Minor cardiac abnormalities:
  Other reported anomalies including the presence of valve
leaflet thickening and regional left ventricular wall motion
abnormality.
Major respiratory abnormality:
  Restrictive defects: Total lung capacity reduced (normal range is
80–120% predicted) with preservation of FEV1/FVC ratio
480%, but evidence of reduced TLCO.
  Obstructive defect: FEV1/FVC o70%.
Minor respiratory abnormality:
  Isolated reduction in TLCO (o80%).
Statistical analysis
Descriptive statistics were calculated using SPSS v11.
RESULTS
Cohort characteristics
A total of 131 women previously treated with mantle radiotherapy
for HL was identified, and of these, 11 were deceased, eight had
a history of breast cancer and 11 were lost to follow-up. The
remaining 101 were invited to attend a specialist clinic for advice
about breast cancer as part of the UK ‘Patient Notification
Exercise’, and 24 declined or did not respond. A total of 77 patients
attended, and of these, 58 women agreed to participate in the late
effects study (Table 1).
Mortality
Of the initial cohort of 131 patients, 12 (9.2%) died including one
woman with oesophageal squamous carcinoma diagnosed during
the study. Five patients died from cardiac causes, four from
secondary cancers, two from respiratory causes and one from
infection.
Second neoplasms
Of the 131 patients, 13 (9.9%) were identified to have had a second
cancer. Eight had a history of breast cancer, two of whom died
from metastatic disease, two patients had a history of basal cell
carcinomas in the radiation field and one patient each had an
oesophageal squamous carcinoma, cardiac sarcoma and lung
cancer, respectively.
Breast screening
Thus far, no incident breast cancers have been identified at the
first breast screen.
Late effects study
Most of the 58 patients included in the late effects study received a
radiation dose of 35Gy in 19 fractions. Of whom, 42 (72%) also
received chemotherapy (10 different regimens, the most frequent
being LOPP (LOPP¼Chlorambucil, Vincristine, Procarbazine,
Prednisolone) and MOPP (MOPP¼Nitrogen Mustard, Vincristine,
Procarbazine, Prednisolone)). Also, 24 women received doxorubicin
and 19 women received bleomycin. as a result of relapse, seven
women also received second-line chemotherapy.
Skin No new cancers were detected during clinical examination,
although one person was referred to dermatology with a suspicious
lesion that was shown to be benign.
Thyroid and parathyroid In all, 21 patients (36.2%) were already
receiving thyroid replacement. Six (10.2%) were found to have
a previously undiagnosed goitre or thyroid nodule and four
(6.8%) untreated women were found to have a raised TSH level,
suggesting undiagnosed hypothyroidism. Of those patients with
goitres, all have undergone surgery with no evidence of
malignancy on histology. Parathyroid hormone and calcium levels
were normal in all patients.
Cardiovascular In all, 10 patients (17.2%) had a major cardiac
abnormality: five had evidence of mixed aortic abnormality; three
had mitral regurgitation, one had a mitral/aortic valve replace-
ment; and five had a reduction in ejection fraction of less than 50%
(Table 2).
Respiratory function Twenty patients had a major respiratory
abnormality: fourteen women (24%) had evidence of airway
obstruction and six women (10.3%) had restrictive lung defect
(Table 2).
Incidence of medical problems Overall, 42 (72%) of the 58 women
who underwent detailed evaluation had a previously undiagnosed
medical problem (Table 2).
DISCUSSION
In a cohort of HL women, mean age 40 years, previously treated
with mantle radiotherapy, 9.2% had died a nonlymphoma-related
death and we found a high incidence of undiagnosed medical
problems in survivors. Impressively, no patient had died of HL. At
a mean of 17 years post-treatment, 72% of women had a medical
problem that could relate to their previous treatment. In addition
to radiotherapy, chemotherapy had also been received by 72% of
patients and it should be recognised that this may contribute to
some late effects (Henry-Amar, 2000). In addition, it is possible
that there is a genetic risk for both HL and late effects, although to
date there is no evidence to support an underlying association
between the two.
We found a 9.9% cumulative incidence of secondary malig-
nancy. This incidence is similar to the 10.6% reported at 20 years
post-treatment in adult survivors of childhood HL (Bhatia et al,
2003), although lower than 21.9% at 25 years in a population of
32591 survivors of HL (Dores et al, 2002). The most common
cancer was breast cancer, as reported previously (Kenney et al,
2004). Increasing age over 50 years is associated with a greater
cancer burden (Dores et al, 2002) and one of our patients aged 57
years was diagnosed and died from oesophageal cancer during the
course of our study. None of this cohort developed leukaemia. The
Table 1 Characteristics of women previously treated with mantle
radiotherapy for HL who participated in late effects study
Detailed late effects study
Characteristic N Mean (range) s.d.
Age at diagnosis (years) 58 23.3 (7–34) 5.8
Time since diagnosis (years) 58 17 (4–36) 8.8
Height (cm) 58 164.6 (151–180) 6.4
Weight (kg) 56 73.3 (47.7–134.0) 16.7
HL¼Hodgkin’s lymphoma; s.d.¼standard deviation.
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srisk of leukaemia in patients treated for HL has been estimated at
0.3% after radiotherapy alone, 2.8% after chemotherapy alone and
5.4% in combined modality therapy (Brusamolino et al, 1998). A
more recent study (Okines et al, 2005) estimated the incidence of
second primary malignancies in patients treated for HL, including
the risk of haematological malignancy. This risk was low at only
0.55% and this is consistent with our findings.
Radiation-induced damage to the heart has been recognised for
some time (Gustavsson et al, 1990; Hancock et al, 1993b; Adams
et al, 2004). The spectrum of damage ranges from constrictive
pericarditis, significant valvular defects, to reduced systolic
dysfunction. In the largest study (Hancock et al, 1993b), of 2232
Hodgkin’s patients, 3.9% died from heart disease and the relative
risk for heart disease was 3.1. The risk was greater with increased
mediastinal radiation and the risk of myocardial infarction
increased with duration of time after treatment. Our results
confirm the high incidence of cardiac abnormalities in this patient
group.
In the lungs, mediastinal radiation appears to create predomi-
nantly a restrictive rather than obstructive defect (Allavena et al,
1992; Gustavsson et al, 1992; Nysom et al, 1998). Hodgkin’s
patients (64–84%) treated with mantle radiotherapy had a
reduction in lung perfusion and perfusion appeared to be more
affected than ventilation, suggesting a primary vascular lesion
(Allavena et al, 1992; Gustavsson et al, 1992). However, in patients
treated during childhood, there was a reduction in lung volumes
as well as transfer factor (Nysom et al, 1998). Our results are
consistent with these observations, although we found a higher
incidence of obstructive defects. This is likely to relate to
confounding environmental factors, including smoking and
occupation.
Hypothyroidism, thyroid nodules and thyroid cancer are well-
recognised complications of mantle radiotherapy (Morgan et al,
1985; Sklar et al, 2000). Consistent with this, we found that 36.2%
of Hodgkin’s patients were already receiving thyroxine treatment.
However, of concern, we found clinically apparent undetected
Table 2 Summary of those identified with abnormalities (patient may have more than one abnormality)
Age at study
(years)
Number of
years of
follow-up
Mantle radiation
dose (Gy)
(fractionation)
Cumulative dose of
doxorubicin (mgm
 2)
Thyroid
abnormality
Echo
abnormality Lung defects
50.1 25 35 (19) Goitre Major Restrictive
30.7 12 38.5 (22) 393.0 Minor Obstructive
34.7 17 35 (19) 240.0 Obstructive
39.1 18 35 (20) Reduced TLCO
38.2 12 35 (20) 330.0 Restrictive
47.4 21 35 (20) Minor
40.9 9 35 (20) 183.0 Reduced TLCO
36.5 6 35 (20) 204.0 Reduced TLCO
47.2 14 35 (20) 360.0 Raised TSH
37.0 5 35 (20) 240.0 Minor
46.7 17 35 (19) 195.0 Obstructive
46.9 26 30 (19) Minor Obstructive
52.6 35 35 (20) Major Obstructive
41.4 7 35 (20) 236.0 Obstructive
41.9 9 35 (20) 284.0 Minor Obstructive
43.2 12 35 (20) Obstructive
36.3 9 35 (20) 195.0 Obstructive
54.2 33 35 (20) Major Obstructive
47.3 25 35 (20) Minor Obstructive
53.4 29 37.5 (24) Raised TSH Reduced TLCO
37.8 23 35 (19) Restrictive
38.6 21 35 (20) Goitre Minor Restrictive
36.1 16 35 (20) Reduced TLCO
41.6 16 35 (20) 270.0 Major
27.1 10 35 (20) 225.0 Restrictive
56.9 36 27.4 (20) Major Restrictive
53.6 27 35 (19) Goitre Major
40.6 27 35 (18) Goitre
41.6 24 35 (19) Goitre
39.2 8 35 (20) Reduced TLCO
47.4 23 35 (19) Major Obstructive
36.6 10 35 (20) Reduced TLCO
33.4 16 35 (20) 480.0 Minor Reduced TLCO
34.5 10 36.75 (21) Major Reduced TLCO
41.6 10 35 (20) 480.0 Raised TSH Reduced TLCO
50.0 31 35 (20) Goitre Major Obstructive
47.8 29 35 (20) Minor
42.5 24 35 (20) Minor Obstructive
36.5 17 35 (20) Reduced TLCO
43.6 28 35 (19) Reduced TLCO
35.3 9 35 (20) Raised TSH
47.7 19 35 (19) Major
TSH¼thyrotropin; TLCO¼transfer factor. Major cardiac abnormalities include: aortic valve disease, mitral regurgitation, mitral and aortic valve replacement and left ventricular
impairment (EFo50%). Minor cardiac abnormalities include: valve leaflet thickening, regional abnormality of LV wall, mild aortic or mitral valvular regurgitation.
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sthyroid nodules in 10.2% of patients and raised TSH levels in 6.8%
of patients. In the data from the Childhood Cancer Survivor Study,
hypothyroidism was the most common disturbance with a relative
risk of 17.1; the relative risk of thyroid nodules compared to a
sibling was 27 and thyroid cancer 18 (Sklar et al, 2000). We found
no abnormality of calcium homeostasis, suggesting that the
parathyroid glands are relatively resistant to radiation-induced
damage, consistent with previous reports (Miltenyi et al, 2004).
We have screened patients treated with mantle radiotherapy as
part of a national recall for breast cancer screening. In the process,
we have identified that this patient group had a high incidence of
undiagnosed late effects of cancer therapy. The mean age of our
patients was 40 years and it is likely that with age, they will have an
increasing burden of late effects and therefore the need for follow-
up increases with time from the end of treatment.
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